Smith & Nephew plc (SNNUF)
| Market Cap | 12.88B |
| Revenue (ttm) | 5.81B |
| Net Income (ttm) | 412.00M |
| Shares Out | n/a |
| EPS (ttm) | 0.47 |
| PE Ratio | 31.26 |
| Forward PE | n/a |
| Dividend | 0.38 (2.52%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 142 |
| Average Volume | 424 |
| Open | 15.00 |
| Previous Close | 14.88 |
| Day's Range | 14.88 - 15.00 |
| 52-Week Range | 11.49 - 15.70 |
| Beta | 0.72 |
| RSI | 72.59 |
| Earnings Date | Feb 25, 2025 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2024, Smith & Nephew's revenue was $5.81 billion, an increase of 4.70% compared to the previous year's $5.55 billion. Earnings were $412.00 million, an increase of 56.65%.
Financial StatementsNews
Smith & Nephew gains after report it may evaluate a break-up
Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research
The global wound care market size was valued at USD 23.13 billion in 2024 and is projected to reach from USD 24.04 billion in 2025 to USD 32.75 billion by 2033, growing at a CAGR of 3.94% during the f...
MARKET REPORT: Recovery hopes breathe life into hip replacement maker Smith & Nephew
Smith & Nephew shares rose 10% in early trading before ending the day up 6.1%, or 64p, to 1107.5p. That took gains for the year to nearly 11%.
We are having constructive engagement with activist shareholders, says Smith & Nephew CEO
Deepak Nath, CEO of Smith & Nephew discusses spin offs, navigating the China market, and the medical tech firm's full-year earnings for 2024.
Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript
Smith & Nephew plc 2024 Q4 - Results - Earnings Call Presentation
Smith & Nephew Non-GAAP EPS of $0.843, revenue of $5.81B
We are having constructive engagement with activist shareholders, says Smith & Nephew CEO
Deepak Nath, CEO of Smith & Nephew discusses, spin offs, navigating the China market, and the medical tech firm's full-year earnings for 2024.
Hip replacement firm Smith & Nephew’s profit surges amid recovery in US sales
The medical technology giant has been in the midst of a turnaround effort, and recently faced calls from its top investors to break the company up.
Smith & Nephew Shares Rise After Higher Profit, Revenue Offset China Headwinds
Earnings Scheduled For February 25, 2025
Companies Reporting Before The Bell • Super Group (SGHC) (NYSE: SGHC) is estimated to report earnings for its fourth quarter. • Carter's (NYSE: CRI) is expected to report quarterly earnings at $1.90...
UK Stock Market News: On The Beach, Unite Group, Smith & Nephew
On The Beach expects a strong summer, return of overseas students boosts Unite, Smith & Nephew outlook upbeat in full year results
UK's Smith+Nephew beats annual profit expectations
Smith+Nephew beat analysts' expectations for annual sales and profit on Tuesday, as a recovery in its U.S. knee and hip implant business, along with cost cuts, helped the medical products maker offset...
FTSE 100 Live 25 February: Smith & Nephew and Croda International post results, index seen lower
Cevian Capital II GP LTD Acquires Significant Stake in Smith & Nephew PLC
Cevian Capital II GP LTD Acquires Significant Stake in Smith & Nephew PLC
Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand
First in market to o ffe r A djustable T ensioning T echnology * for i nsertional A chilles r econstruction and l ateral a nkle i nstability r epair
Martin Cobb's Top Picks: Saputo, Smith & Nephew and Electronic Arts
Martin Cobb, senior vice-president of equities at Lorne Steinberg Wealth Management shares his top stock picks; Saputo, Smith & Nephew and Electronic Arts.
Smith+Nephew and UFC to host first-of-its-kind medical education course for treatment of injuries in combat sport athletes
Healthcare professionals are invited to register for the livestream option as a courtesy here
Smith & Nephew Getting No Credit For Self-Improvement Efforts ... But Should It?
Smith & Nephew's stock underperformance due to market share losses & pricing pressures in China.
Smith & Nephew (SNN) Stock Surges Amid Strong Financial Performance
Smith & Nephew (SNN) Stock Surges Amid Strong Financial Performance
Smith & Nephew PLC (SNN) Receives Favorable Ratings for Advanced Wound Care Solutions
Smith & Nephew PLC (SNN) Receives Favorable Ratings for Advanced Wound Care Solutions
Smith+Nephew's ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable' Evidence Bar™ ratings from ECRI for pressure injury prevention
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence A...
Topical Scar Treatment Market to Grow from $1.71 Billion in 2024 to $5.91 Billion by 2035 - Dominated by Smith & Nephew, Molnlycke Health Care, Alliance Pharma, HRA Pharma, and Rejuvaskin
Scar Treatment Market Booms with Rising Skin-Related Surgeries and Burn Cases Globally Scar Treatment Market Booms with Rising Skin-Related Surgeries and Burn Cases Globally
Smith & Nephew chief Deepak Nath in 'last chance saloon'
They will pressure Nath to resign in the New Year unless he proves that the FTSE 100 firm has made operational improvements.
Smith & Nephew PLC (SNN) Expands CORI Surgical System with FDA-Cleared Hip Arthroplasty Planning
Smith & Nephew PLC (SNN) Expands CORI Surgical System with FDA-Cleared Hip Arthroplasty Planning